SwanBio Therapeutics, a gene therapy company, has named Steven Zelenkofske, DO, MS as its new chief medical officer, it was reported on Monday.
Dr Zelenkofske has over 20 years of experience. Prior to joining SwanBio Therapeutics, he served as the CMO at Achillion Pharmaceuticals and at UniQure. He has held leadership positions at Regado Biosciences, Astra-Zeneca, Sanofi-Aventis, Boston Scientific and Novartis. His work includes various therapeutic areas including neurology, immunology, haematology, cardiovascular, metabolic diseases, diabetes, and nephrology.
Tom Anderson, CEO and director of SwanBio Therapeutics, said, 'We are thrilled to add Steven's expertise to our leadership team. His background complements the extensive talent and experience of our existing management team and will help support our goal of developing gene therapies in neurological diseases that deliver real benefit to patients and their families.'
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults